by RNA | Apr 20, 2022 | Client Success, Strategic Advisory, Valuation Advisory
By Jeff Williamson THE SITUATION: A healthcare company with a portfolio of products in development for treating cardiac conditions was fielding investor interest for a potential acquisition. The company wanted to weigh the relative merits of raising additional equity... Read More
by RNA | Apr 20, 2022 | Client Success, Valuation Advisory
By Jeff Suchocki, CFA The Situation: Adoption of ASC 842 – Lease Accounting is mandatory for all private companies for fiscal years beginning after December 15, 2021. To comply with this mandatory adoption requirement, a privately held, clinical stage biotech company... Read More
by RNA | Jul 20, 2021 | Client Success, Strategic Advisory
By Jeff Williamson THE SITUATION: A medical device company was preparing to launch a novel product used in interventional cardiac surgeries — one that offered improved performance, simplified clinical workflows, and reduced procedure times. The company asked... Read More
by RNA | Nov 10, 2020 | Client Success, Strategic Advisory, Valuation Advisory
THE PROBLEM: A healthcare technology company that sells its FDA 510(k) approved device and supporting dashboarding and analytic tools to hospitals was in the midst of a capital raising effort involving a one-on-one negotiation with an existing strategic partner. The... Read More
by RNA | Jul 25, 2019 | Client Success, Strategic Advisory, Valuation Advisory
THE PROBLEM: A publicly traded clinical stage biotech company needed to understand the correct implied discount rate for a lease agreement in accordance with ASC 842 rules. THE SOLUTION: ASC 842 has specific rules relating to leases, including guidance on lease... Read More
by RNA | Jul 3, 2019 | Client Success, Strategic Advisory
THE PROBLEM: A medtech start-up with a leading CE-marked product faced a strategic resource allocation decision: invest in next-generation technology in the current low-growth market, or place bets on riskier technologies in the emerging higher growth segment? THE... Read More
